Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 18Recruiting 13Terminated 8Unknown 5Active not recruiting 3Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Glioma 1Ependymoma 1Choroid Plexus Carcinoma 1Brain Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Hematopoietic Stem Cell Transplantation × Clear all
NCT04521946 2024-10-26

Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNS

Choroid Plexus Carcinoma, Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Roswell Park Cancer Institute

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡